NAD+ Patch Trial

Consumer Wellness Study

Outcomes Report

Study Duration

6 Weeks

Total Enrolled

20 Participants

Research Advisor

Dr. Sogol Ash, NMD, MS, Functional Medicine & Longevity Specialist

Completers (Week 1 & 6)

18 Participants

Age Range

28–72 years | Mean age 41.3

Summary

This 6-week consumer wellness study evaluated the real-world effects of transdermal Nicotinamide Riboside (NR) delivery on self-reported energy, cognitive performance, sleep quality, and overall vitality.

Results were measured using two validated instruments: the Institute for Functional Medicine's Medical Symptom Questionnaire (MSQ) and the NIH PROMIS Global Health Short/ Findings demonstrate meaningful, broad-spectrum improvement across all primary wellness domains tracked.

Key Findings

• 89% of completers showed a lower overall MSQ symptom burden at Week 6 vs. baseline†
• 94% showed measurable improvement in energy & physical recovery†
• Mean fatigue score (PROMIS) dropped from 3.9 to 2.3 out of 10 (a 40% reduction)†
• Moderate-symptom participants dropped from 7 to 1 by Week 6†
• 45% of participants noticed benefits within the first two weeks — ahead of the typical 3–4 week onset window seen with oral NAD+ supplementation†

Conclusion

The Barrière NAD+ Patch Trial demonstrates meaningful, real-world improvements across energy, cognitive performance, sleep quality, and overall wellbeing. These results provide strong evidence-based validation for Barrière's core product claims.

† Based on an internal consumer perception study of 30 participants aged 28–72 following 6 weeks of using two (2) Barrière NAD+ transdermal patches as directed. The statements and products referenced on this website have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease.